Stephen Rocamboli

Stephen Charles Rocamboli was the founder of Pear Tree Pharmaceuticals, Inc., founded in 2008, where the titles held included President & Secretary from 2008 to 2018.
Current jobs include Director at Cortice Biosciences, Inc. and Director at Androvia Life Sciences.
Former jobs include Chairman & Chief Executive Officer at Perla Therapeutics, Inc.; Non-Executive Chairman & Secretary at VioQuest Pharmaceuticals, Inc. from 2003 to 2009; Senior Managing Director & General Counsel at Paramount BioCapital, Inc. from 2004 to 2007; Director at Cutanea Life Sciences, Inc.; Director at Foresight Biotherapeutics, Inc.; Independent Director at TFF Pharmaceuticals, Inc. from 2018 to 2024; Independent Director at Esperion Therapeutics, Inc. from 2022 to 2026; President & Secretary at Chitina Sciences, Inc. in 2007; President & Secretary at Cordova Sciences, Inc.; Special Counsel at Wyrick Robbins Yates & Ponton LLP from 2014 to 2015; Partner at Orion Biomedical Fund LP from 1999 to 2007; Deputy General Counsel at Paramount BioSciences LLC from 1999 to 2004; Secretary & Chief Business Officer at Candel Therapeutics, Inc. from 2015 to 2020; General Partner at Integrin Partners LLC from 2010 to 2015; and Partner at Beijing International Group LLC from 2010 to 2012.
Education includes undergraduate studies at State University of New York at Albany and graduate studies at Fordham University School of Law.